OTHER Research papers

Journal of Crohn's and Colitis, 2023 Nov 29:jjad195. doi: 10.1093/ecco-jcc/jjad195
A Core Outcome Set for inflammatory bowel diseases: development and recommendations for implementation in clinical practice through an international multi-stakeholder consensus process

Journal of Crohn's and Colitis, Volume 17, Issue 8, August 2023, Pages 1342–1353
Artificial Intelligence in Inflammatory Bowel Disease Endoscopy: Implications for Clinical Trials

N Engl J Med 2023; June: 388:2444-2455 DOI: 10.1056/NEJMoa2207940
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis

Journal of Crohn's and Colitis, Volume 17, Issue 7, July 2023, Pages 1139–1153.
Systematic Review with Meta-analysis: The Impact of Cancer Treatments on the Disease Activity of Inflammatory Bowel Diseases

Lancet Child Adolesc Health. 2023 Jun 27:S2352-4642(23)00136-0. doi: 10.1016/S2352-4642(23)00136-0. Epub ahead of print. PMID: 37390832.
Immunological effects and safety of live rotavirus vaccination after antenatal exposure to immunomodulatory biologic agents

Immunological effects and safety of live rotavirus vaccination after antenatal exposure to immunomodulatory biologic agents: a prospective cohort study from the Canadian Immunization Research Network

IBD-EII platform to help share evidence-based data regarding IBD in a summarized way.

Gastroenterology American Gastroenterology Association: Published: March 03, 2023DOI:https://doi.org/10.1053/j.gastro.2023.02.031
Artificial Intelligence Enabled Histological Prediction of Remission or Activity and Clinical Outcomes in Ulcerative Colitis

Gastroenterology American Gastroenterology Association: Published: March 03, 2023DOI:https://doi.org/10.1053/j.gastro.2023.02.031

The Lancet Gastroenterology and Hepatology: VOLUME 8, ISSUE 3, P215-227, MARCH 2023
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial

Research papers

Journal of Crohn's and Colitis, 2023 Nov 29:jjad195. doi: 10.1093/ecco-jcc/jjad195 A Core Outcome Set for inflammatory bowel diseases: development and recommendations for implementation in clinical practice through an international multi-stakeholder consensus process

Journal of Crohn's and Colitis, Volume 17, Issue 8, August 2023, Pages 1342–1353 Artificial Intelligence in Inflammatory Bowel Disease Endoscopy: Implications for Clinical Trials

N Engl J Med 2023; June: 388:2444-2455 DOI: 10.1056/NEJMoa2207940 Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis

Journal of Crohn's and Colitis, Volume 17, Issue 7, July 2023, Pages 1139–1153. Systematic Review with Meta-analysis: The Impact of Cancer Treatments on the Disease Activity of Inflammatory Bowel Diseases

Lancet Child Adolesc Health. 2023 Jun 27:S2352-4642(23)00136-0. doi: 10.1016/S2352-4642(23)00136-0. Epub ahead of print. PMID: 37390832. Immunological effects and safety of live rotavirus vaccination after antenatal exposure to immunomodulatory biologic agents

IBD-EII platform to help share evidence-based data regarding IBD in a summarized way.

Gastroenterology American Gastroenterology Association: Published: March 03, 2023DOI:https://doi.org/10.1053/j.gastro.2023.02.031 Artificial Intelligence Enabled Histological Prediction of Remission or Activity and Clinical Outcomes in Ulcerative Colitis

The Lancet Gastroenterology and Hepatology: VOLUME 8, ISSUE 3, P215-227, MARCH 2023 Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial

Journal of Crohn's and Colitis, 2023 Nov 29:jjad195. doi: 10.1093/ecco-jcc/jjad195
A Core Outcome Set for inflammatory bowel diseases: development and recommendations for implementation in clinical practice through an international multi-stakeholder consensus process

Journal of Crohn's and Colitis, Volume 17, Issue 8, August 2023, Pages 1342–1353
Artificial Intelligence in Inflammatory Bowel Disease Endoscopy: Implications for Clinical Trials

N Engl J Med 2023; June: 388:2444-2455 DOI: 10.1056/NEJMoa2207940
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis

Journal of Crohn's and Colitis, Volume 17, Issue 7, July 2023, Pages 1139–1153.
Systematic Review with Meta-analysis: The Impact of Cancer Treatments on the Disease Activity of Inflammatory Bowel Diseases

Lancet Child Adolesc Health. 2023 Jun 27:S2352-4642(23)00136-0. doi: 10.1016/S2352-4642(23)00136-0. Epub ahead of print. PMID: 37390832.
Immunological effects and safety of live rotavirus vaccination after antenatal exposure to immunomodulatory biologic agents

Gastroenterology American Gastroenterology Association: Published: March 03, 2023DOI:https://doi.org/10.1053/j.gastro.2023.02.031
Artificial Intelligence Enabled Histological Prediction of Remission or Activity and Clinical Outcomes in Ulcerative Colitis

The Lancet Gastroenterology and Hepatology: VOLUME 8, ISSUE 3, P215-227, MARCH 2023
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial